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To develop effective vaccines against infection with human T cell leukaemia virus type I (HTLV-I), we constructed a recombinant vaccinia virus (WR-SFB5env) synthesizing the HTLV-I envelope (Env)
gp46 protein under the control of a strong promoter, termed the ATI hybrid promoter. WR-SFB5env expressed a large quantity of gp46. In cynomolgus monkeys (Macaca fascicularis) immunized with WR-SFB5env, anti-HTLV-I Env antibody, including neutralizing antibody, was induced and remained at a high level until 136 weeks (2n6 years) post-infection (p.i.). These immunized monkeys had HTLV-I Env-specific cytotoxic T lymphocyte activity. At 136 weeks p.i., the immunized monkeys were challenged with an HTLV-I-producing cynomolgus T lymphocyte cell line. Neither HTLV-I antigen nor HTLV-I proviruses were detected in peripheral blood mononuclear cells, lymph nodes or spleens of the WR-SFB5envimmunized monkeys, in contrast to non-immunized control monkeys. These results indicate that a single immunization with WR-SFB5env induced prolonged humoral and cellular immune responses to HTLV-I and protected the monkeys against virus challenge.
Human T cell leukaemia virus type I (HTLV-I), the first human retrovirus to be discovered, was isolated in 1980 from a patient with cutaneous T cell lymphoma (Poiesz et al., 1980) . Infection with HTLV-I is implicated in the aetiology of adult T cell leukaemia (ATL) (Poiesz et al., 1980 ; Hinuma et al., 1981) and several other diseases.
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Fax j81 75 761 5626. e-mail hshida!virus1.virus. kyoto-u.ac.jp The major routes of HTLV-I transmission are maternal transmission through milk (Ichimaru et al., 1991) , blood transfusion (Okochi et al., 1984) and sexual transmission (Kajiyama et al., 1986) . To prevent transmission, avoidance of breast feeding and screening of blood donations have been employed in Japan (Ichimaru et al., 1991) , but such measures cannot be implemented in other endemic areas because of public health and economic problems (de The et al., 1993) .
The envelope (Env) glycoprotein of HTLV-I is a major antigen recognized by the humoral and cellular immune responses in individuals infected with HTLV-I (Schupbach et al., 1984 ; Jacobson et al., 1991) . Polyclonal and monoclonal antibodies to HTLV-I Env proteins, including gp46, have been demonstrated to neutralize HTLV-I infection (Clapham et al., 1984 ; Nagy et al., 1983 ; Tanaka et al., 1991 Tanaka et al., , 1994 . Thus, to develop an effective vaccine against HTLV-I, Env proteins, including gp46, should be the first candidates.
Previously, we and other groups constructed recombinant poxviruses expressing the authentic env gene of HTLV-I and showed that they protected vaccinated rabbits against HTLV-I infection (Shida et al., 1987 ; Franchini et al., 1995) . However, a monkey model of HTLV-I infection should be closer to human infection than the rabbit model. Thus we examined the effect of a recombinant vaccinia virus (rVV) vaccine in monkeys.
In the present study, we constructed an rVV, named WR-SFB5env, synthesizing the gp46 Env protein of HTLV-I and investigated its immunogenicity and ability to protect monkeys against HTLV-I infection.
WR-SFB5env was constructed using plasmid pSFB5, which contains the A-type inclusion body (ATI) promoter of cowpox virus and five units of synthetic VV 7n5 kDa early promoter, flanked with segments of the vaccinia virus HA gene as described before (Funahashi et al., 1991) . WR-proenv1, which expresses the env gene under the control of the 7n5 kDa promoter, was described previously (Shida et al., 1987) .
To determine whether the HTLV-I Env protein was 0001-4203 # 1997 SGM Protective immunity conferred by HTLV-I Env Protective immunity conferred by HTLV-I Env synthesized by WR-SFB5env, in comparison with WR-proenv1, rabbit kidney cells (RK13) infected with these viruses were examined by Western blot (WB) using rat anti-gp46 MAb (LAT27) or rabbit anti-ATI antibody as described previously (Tanaka et al., 1990) . As shown in Fig. 1 (a) , both rVVs synthesized gp46, but WR-SFB5env produced severalfold more gp46 protein than WR-proenv1. Furthermore, large amounts of higher molecular mass bands were evident in the lane corresponding to WR-proenv1-infected cells, suggesting the incomplete processing of the precursor Env proteins. Fig.  1(b) shows both rVVs produced the same amount of ATI protein, a major VV protein, indicating that both propagated similarly in RK13 cells. The cell surface localization of the Env protein was confirmed by immunofluorescence assay (IFA) by the method described previously (Shida et al., 1987) . These results demonstrated that the HTLV-I Env proteins are synthesized more efficiently by WR-SFB5env than WR-proenv1 and transported normally to the cell surface.
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To determine the basis of differences in processing of the Env protein in cells infected with each rVV, we sequenced the HTLV-I envelope gene portion of WR-proenv1 and WR-SFB5env after PCR amplification. The env gene of WR-SFB5env had one insertion of cytosine at position 6458 which introduced a stop codon (aa 430) in the region coding for the membrane-spanning domain of gp21 (data not shown). To confirm this result, the Env proteins synthesized by the rVVs were immunoprecipitated by human anti-HTLV-I sera and analysed by SDS-PAGE according to Shida et al. (1987) ; gp21 was not detected in the WR-SFB5env-infected cells (Fig. 1 c) .
Since WR-SFB5env synthesized more gp46 protein than WR-proenv1, we used WR-SFB5env for immunization. Five cynomolgus monkeys (two females, T9 and T13, and three males, T10, T11 and T14 ; 2 years old) were examined and found to be free of simian T cell leukaemia virus type I and HTLV-I by PCR (see below), the particle agglutination (PA) method (Serodia-HTLV-I ; Fujirebio) and WB (PROBLOT HTLV-I ; Fujirebio). Two monkeys (T10 and T14) were immunized intradermally with 3i10) p.f.u. of WR-SFB5env and three monkeys (T9, T11 and T13) received an injection of 3i10) p.f.u. of HA − VV, a mutant VV. Two WR-SFB5envimmunized monkeys started to produce anti-HTLV-I-specific antibodies within 2 weeks after inoculation and maintained high titres of anti-HTLV-I antibodies for 136 weeks postinfection (p.i.). The anti-gp46 antibodies in these plasma samples were detected by WB analysis (Table 1) .
To determine whether neutralizing antibodies against HTLV-I were induced, we examined the cell fusion inhibition activity of the monkey plasma as described by Tanaka et al. (1990 Tanaka et al. ( , 1991 Tanaka et al. ( , 1994 . A rabbit anti-gp46 serum, obtained from a rabbit that had been immunized with an envelope-derived peptide (pep180-204) and resisted HTLV-I infection (Tanaka et al., 1994) , was used as a positive control. As shown in Table  1 , plasma samples obtained 119 weeks p.i. from the two immunized monkeys (T10 and T14) showed cell fusion inhibition activity even at 20-and 10-fold dilution, respectively, which was equivalent to the positive control serum. In contrast, their preimmune plasma and those from three control monkeys at 119 weeks p.i. had no inhibitory effect. Anti-VV neutralizing antibodies reached a peak at 8 weeks p.i. and declined to 1\10 level at 119 weeks p.i., suggesting that the rVV did not persist in the monkeys (data not shown).
To determine whether the rVV induced cytotoxic T lymphocytes (CTL) specific to HTLV-I, we isolated peripheral blood mononuclear cells (PBMC) from the immunized monkeys 119 weeks p.i. and assayed CTL activity after in vitro stimulation three times for 2 weeks with autologous HTLV-Iinfected T cells (T-LCLs), which had been established according to the method described by Kannagi et al. (1983) . These autologous T-LCLs were also used as target cells for assaying CTL activity. In addition, we established B lymphocyte cell lines (B-LCL) from individual monkeys using herpesvirus papio-producing S594 cells (Yamamoto et al., 1990) and infected these with rVV expressing each HTLV-I gene (Shida et al., 1987) to prepare target cells expressing HTLV-I env, gag, tax, rex and p21 gene products. After the target cells were labelled with &"Cr, peripheral blood lymphocytes that had been stimulated in vitro were added at several effector : target (E : T) ratios and the release of &"Cr from the target cells was measured (Yamamoto et al., 1990) . Cells from immunized monkey T10 showed significant cytotoxicity against autologous T-LCL and autologous B-LCL infected with rVV expressing HTLV-I env (Table 1) . These CTL showed no No. 0 2 4 6 8 10 12 16 20 24 28 32 51 at necropsy at necropsy HTLV-I antigens* WR-SFB5env T10 k k k k k k k k k k k k k k k T14 k k k k k k k k k k k k k k k HA − VV T9 k k j k j j k j j j j j j j j T11 k k j k  k j j j j j j j j j T13 k k j k j k j j j j j j j j 
k j  k  k  j  j j j j j j * HTLV-I antigen was examined by IFA in cultured PBMCs from experimental monkeys. † The presence of virus DNA was examined by PCR in both uncultured and cultured PBMCs, lymph nodes or spleen cells.
cytotoxic activity against target cells expressing HTLV-I gag, tax, rex or p21 or those infected with control VV. Furthermore these CTL did not lyse either heterologous T-LCL or K562 cells, which are target cells for natural killer cells (data not shown). Immunized monkey T14 had marginal CTL activity specific to HTLV-I. The CTL from control monkeys at 119 weeks p.i. had no specific CTL activity to HTLV-I. These observations indicated that the CTLs were capable of killing autologous target cells expressing HTLV-I Env protein.
To determine whether the vaccinated monkeys were protected against HTLV-I infection, 2i10( cells of an HTLV-I-producing T cell line from a macaque monkey (6CM) (Nakamura et al., 1987) were inoculated intravenously into the monkeys 136 weeks p.i. To detect HTLV-I antigen in lymphocytes of the challenged monkeys, PBMC were separated from heparinized whole blood and cultured for 4-10 weeks. A fraction of the cultured cells was examined every week by IFA for HTLV-I antigen (Nakamura et al., 1987) and by PCR for HTLV-I provirus as described by Yamashita et al. (1995) . At 51 weeks post-challenge (p.c.), lymph nodes and spleens from these monkeys were obtained at necropsy and examined as described above. This PCR method has been shown to detect one copy of the HTLV-I genome (K. Ibuki, S. Funahashi, H. Yamamoto, M. Nakamura, T. Igarashi, T. Miura, E. Ido, M. Hayami and H. Shida, unpublished results) . As shown in Table 2 , the HTLV-I antigen was detected in the PBMC of all the control monkeys throughout the observation period (up to 51 weeks p.c.) and in their lymph nodes and spleen. In contrast, no virus antigen was detected in the PBMC, lymph nodes or spleens of WR-SFB5env-immunized monkeys. Moreover, the presence of virus DNA in PBMC, lymph nodes and spleen was demonstrated by PCR only in the control monkeys. After challenge, the titres of anti-HTLV-I antibodies in WR-SFB5env-immunized monkeys were not significantly changed. In contrast the control monkeys produced anti-HTLV-I-specific antibodies within 6 weeks p.c. and their titres increased gradually during the observation period (Table 1) . These results suggest that the monkeys vaccinated with WR-SFB5env may be protected from HTLV-I infection.
The present data indicated that a single immunization with WR-SFB5env elicited long-lived anti-Env antibodies as well as Env-specific CTL activity in cynomolgus monkeys and protected the monkeys against HTLV-I infection. The fact that gp46 expression alone was sufficient for protection may be due to the presence in gp46 of epitope targets for neutralization and HLA class I-or class II-restricted CTL (Jacobson et al., 1991 ; Katahira et al., 1995 ; Tanaka et al., 1991 Tanaka et al., , 1994 .
The fact that the plasma from these monkeys 119 weeks p.i. showed significant cell fusion inhibition activity is important since cell-to-cell infection by cell fusion (Nagy et al., 1983 ; Okochi et al., 1984) has been shown to be a major route of HTLV-I infection. In fact, Sawada et al. (1991) reported that passive immunization with HTLV-I-immune human or rabbit serum protected newborn rabbits against milk-borne transmission from their mothers. Therefore, these observations indicated that in immunized macaque monkeys, protective antibodies were induced effectively.
In addition to cell fusion inhibition antibodies, vaccination with WR-SFB5env induced and maintained Env-specific CTL for more than 100 weeks p.i. Gatei et al. (1993) reported that effective cellular immunity, possibly CTL, against the envelope glycoproteins of bovine leukaemia virus (BLV), closely related to HTLV-I, may have excluded the infecting BLV. Thus not only antibody-mediated but also cell-mediated immunity could have a protective effect against HTLV-I infection. Hakoda et al. (1995) reported that WR-SFB5env failed to Protective immunity conferred by HTLV-I Env Protective immunity conferred by HTLV-I Env induce neutralizing antibodies in rabbits and protected them incompletely. We compared the plasma prepared from the immunized monkeys and rabbits (a kind gift from I. Miyoshi, Kochi Medical School, Japan) side by side and confirmed that these rabbits' sera had no significant cell fusion inhibition activity in contrast to the monkey plasma (data not shown). This may represent a species-related difference in immune response. Env peptide vaccines have been reported to induce anti-gp46 neutralizing antibodies in rabbits and cynomolgus monkeys and to protect them from HTLV-I challenge (Tanaka et al., 1994 ; Nakamura et al., 1987) . Although the Env peptides were effective in conjunction with adjuvant (e.g. Freund's complete adjuvant), repeated immunizations were necessary. Our results suggest the feasibility of inducing long-lived protective immunity without frequent immunization, implying that rVV expressing the HTLV-I env gene is a promising approach for vaccine development against HTLV-I. Since we used only two monkeys, further studies with more monkeys will be necessary to confirm the protective effect of WR-SFB5env.
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